Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

Background: The optimal aspirin dose for the prevention of cardiovascular events remains
controversial. Objective: To assess the incidence of and risk factors for adverse clinical …

Background Aspirin and clopidogrel monotherapies are effective treatments for preventing
vascular disease. However, new evidence has emerged regarding the use of combined …

Background Repeat hospitalizations of patients with atherosclerosis represent a
considerable burden on the health care system. We sought to determine whether …

Background and Purpose—The goal of this study was to examine the influence of
preexisting symptomatic atherosclerotic disease on subsequent ischemic event rates and …

Background There is no clear consensus on whether aspirin offers better outcomes in terms
of secondary cardiovascular disease prevention compared with clopidogrel. Objective The …

Background—Clinical trial data associate extended clopidogrel therapy with increased
mortality and cancer. We sought to determine the impact of continued clopidogrel use on …

In “Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to
Antiplatelet Monotherapy for the Prevention of Vascular Events,” Bowry et al 1 found that …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …

Clopidogrel has been evaluated across the spectrum of secondary and primary prevention.
Initially, the CAPRIE trial randomized patients with recent myocardial infarction, ischemic …